Ilyang Pharmaceutical Co Ltd - Asset Resilience Ratio
Ilyang Pharmaceutical Co Ltd (007575) has an Asset Resilience Ratio of 2.46% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is Ilyang Pharmaceutical Co Ltd's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2024)
This chart shows how Ilyang Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. See debt-free asset ratio of Ilyang Pharmaceutical Co Ltd to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down Ilyang Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Ilyang Pharmaceutical Co Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩10.93 Billion | 2.46% |
| Total Liquid Assets | ₩10.93 Billion | 2.46% |
Asset Resilience Insights
- Limited Liquidity: Ilyang Pharmaceutical Co Ltd maintains only 2.46% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Ilyang Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio
Compare Ilyang Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 11.60% |
|
SIMCERE PHARMAC. GRP LTD
F:S2P |
Drug Manufacturers - Specialty & Generic | 0.44% |
|
Curaleaf Holdings Inc.
TO:CURA |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
|
Renhe Pharmacy Co Ltd
SHE:000650 |
Drug Manufacturers - Specialty & Generic | 37.54% |
Annual Asset Resilience Ratio for Ilyang Pharmaceutical Co Ltd (2014–2024)
The table below shows the annual Asset Resilience Ratio data for Ilyang Pharmaceutical Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 1.97% | ₩8.49 Billion ≈ $5.76 Million |
₩431.21 Billion ≈ $292.23 Million |
+0.07pp |
| 2023-12-31 | 1.90% | ₩6.78 Billion ≈ $4.59 Million |
₩356.66 Billion ≈ $241.70 Million |
+0.81pp |
| 2022-12-31 | 1.09% | ₩5.42 Billion ≈ $3.67 Million |
₩498.19 Billion ≈ $337.61 Million |
-5.86pp |
| 2021-12-31 | 6.95% | ₩34.34 Billion ≈ $23.27 Million |
₩494.27 Billion ≈ $334.96 Million |
+6.89pp |
| 2020-12-31 | 0.06% | ₩270.87 Million ≈ $183.56K |
₩439.12 Billion ≈ $297.58 Million |
+0.05pp |
| 2019-12-31 | 0.01% | ₩43.52 Million ≈ $29.49K |
₩437.46 Billion ≈ $296.46 Million |
-1.25pp |
| 2018-12-31 | 1.26% | ₩5.46 Billion ≈ $3.70 Million |
₩432.25 Billion ≈ $292.93 Million |
+0.51pp |
| 2017-12-31 | 0.76% | ₩3.31 Billion ≈ $2.24 Million |
₩436.37 Billion ≈ $295.72 Million |
+0.75pp |
| 2016-12-31 | 0.01% | ₩43.85 Million ≈ $29.72K |
₩431.26 Billion ≈ $292.26 Million |
-0.07pp |
| 2015-12-31 | 0.08% | ₩354.85 Million ≈ $240.48K |
₩431.63 Billion ≈ $292.51 Million |
-0.05pp |
| 2014-12-31 | 0.13% | ₩581.48 Million ≈ $394.06K |
₩430.83 Billion ≈ $291.97 Million |
-- |
About Ilyang Pharmaceutical Co Ltd
Ilyang Pharmaceutical Co.,Ltd operates as a pharmaceutical company primarily in South Korea. The company offers anticancer, circulatory system, endocrine/metabolism, cheonjiyang, female hormone, urinary system, ophthalmology, liver disease, anti-inflammatory analgesic, digestive system, dermatology, respiratory system, nutrient infusion, and neurology medicines. It also provides antibiotics, anti… Read more